Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lansoprazole Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.

NCT00237068
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole; Solutab
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Not applicable Interventional

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679
View directory record Official record
Conditions
Voice Disorders, Gastroesophageal Reflux
Interventions
Neuromuscular Electrical Stimulation, Unstimulated
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 2, 2026, 2:04 PM EDT
Not listed Not applicable Interventional

Prevacid vs Lifestyle Modifications for the Treatment of LPR

NCT00274339
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Prevacid 30mg BID, Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.
Drug · Behavioral
Lead sponsor
Hodge, Kenneth M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2007 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

NCT02334501
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

NCT02615184
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Not applicable Interventional Results available

COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

NCT00523367
View directory record Official record
Conditions
Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
Interventions
24 hour pH testing
Procedure
Lead sponsor
University of Florida
Other
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

NCT00627016
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

NCT02128490
View directory record Official record
Conditions
Gout, Moderate Renal Impairment
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
89
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated No phase listed Observational

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

NCT00624546
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux
Interventions
Prevacid Solutabs, Antireflux surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Elucidation of Acid-Induced Pulmonary Inflammation

NCT00361972
View directory record Official record
Conditions
Gastroesophageal Reflux, Asthma
Interventions
lansoprazole, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

NCT00638456
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide plus Prevacid, placebo plus Prevacid
Drug
Lead sponsor
Ranjan Dohil
Other
Eligibility
1 Year and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

NCT05050188
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
H008, H008 placebo, Lansoprazole
Drug
Lead sponsor
Jiangsu Carephar Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Phase 4 Interventional Results available

The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors

NCT01404832
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
Interventions
Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2940680 in Healthy Participants

NCT01681186
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

NCT02616302
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 4 Interventional Results available

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

NCT01093755
View directory record Official record
Conditions
Inflammation, Barrett's Esophagus
Interventions
dexlansoprazole, Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00390390
View directory record Official record
Conditions
Heartburn
Interventions
Lansoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
30
States / cities
Mobile, Alabama • Little Rock, Alaska • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

NCT00685295
View directory record Official record
Conditions
Pain, Fracture, Sprain
Interventions
Fentanyl, Lansoprazole, Oxycodone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

NCT00369265
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Lansoprazole, Sugar pill
Drug · Dietary Supplement
Lead sponsor
American Institute for Voice and Ear Research
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 2, 2026, 2:04 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

NCT01317472
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
dexlansoprazole, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn

NCT01037452
View directory record Official record
Conditions
Heartburn
Interventions
Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 2, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00255190
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
181
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 2, 2026, 2:04 PM EDT